LANDOS BIOPHARMA Revenue and Competitors
Estimated Revenue & Valuation
- LANDOS BIOPHARMA's estimated annual revenue is currently $7.6M per year.
- LANDOS BIOPHARMA's estimated revenue per employee is $201,000
Employee Data
- LANDOS BIOPHARMA has 38 Employees.
- LANDOS BIOPHARMA grew their employee count by 0% last year.
LANDOS BIOPHARMA's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Clinical Operations | Reveal Email/Phone |
2 | VP Project Leadership (Program Team Leader) and Site Engagement Strategy | Reveal Email/Phone |
3 | Director, Operations & Administration | Reveal Email/Phone |
4 | Director | Reveal Email/Phone |
5 | Director SEC Reporting & Budgeting | Reveal Email/Phone |
6 | Medical Director | Reveal Email/Phone |
7 | Chief Medical Officer | Reveal Email/Phone |
8 | Clinical Project Manager | Reveal Email/Phone |
9 | Project Manager | Reveal Email/Phone |
10 | HR Manager | Reveal Email/Phone |
LANDOS BIOPHARMA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.9M | 79 | 25% | $210M | N/A |
#2 | $30.2M | 182 | N/A | N/A | N/A |
#3 | $6.6M | 33 | 6% | N/A | N/A |
#4 | $7.8M | 39 | -39% | N/A | N/A |
#5 | $4.8M | 24 | 4% | N/A | N/A |
#6 | $12.5M | 62 | 7% | N/A | N/A |
#7 | $22.1M | 110 | 7% | N/A | N/A |
#8 | $11.7M | 58 | -9% | N/A | N/A |
#9 | $5.8M | 29 | -12% | N/A | N/A |
#10 | $42.4M | 211 | N/A | N/A | N/A |
What Is LANDOS BIOPHARMA?
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. BT-11, Landos' lead asset, is completing a Phase 2 trial in mild to moderate ulcerative colitis (UC) in the U.S. Europe and Russia, with plans to initiate a Phase 2 trial of BT-11 in moderate to severe Crohn's disease (CD). BT-11 is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$7.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
LANDOS BIOPHARMA News
Jefferies Financial Group Weighs in on Landos Biopharma, Inc.'s Q2 2022 Earnings (NASDAQ:LABP). Posted by admin on Apr 14th, 2022.
Jefferies Financial Group has a Hold rating on the stock. Jefferies Financial Group also issued estimates for Landos Biopharma's Q3 2022...
Landos Biopharma, Inc. (NASDAQ:LABP) Receives $12.65 Consensus PT from Analysts. Posted by admin on Apr 16th, 2022.
Other Companies in Blacksburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.7M | 38 | -19% | N/A |
#2 | $4.8M | 41 | 0% | N/A |
#3 | $5.2M | 43 | 8% | N/A |
#4 | $6.3M | 44 | -12% | N/A |
#5 | $6.6M | 46 | 188% | N/A |